Tirzepatide vs Cagrilintide

A dual GIP and GLP-1 receptor agonist producing the largest sustained weight reductions of any drug currently licensed, averaging 20–22% body weight loss in clinical trials.

A long-acting amylin analogue developed by Novo Nordisk. On its own it produces modest weight loss; paired with semaglutide (CagriSema), it exceeds tirzepatide in trials.

Tirzepatide activates both GIP and GLP-1 receptors, a combination that appears to amplify glucose-dependent insulin secretion, slow gastric emptying, and suppress appetite beyond what either pathway achieves alone.

Cagrilintide activates amylin and calcitonin receptors, delaying gastric emptying and suppressing appetite through a mechanism complementary to GLP-1 receptor agonism.

2.5 mg weekly, titrated up to 15 mg weekly

2.4 mg subcutaneous weekly (matched to semaglutide)

~5 days

~7 days

Subcutaneous once weekly

Subcutaneous

approved

investigational

Not yet listed

Not yet listed